CAS: 65873-72-5; 6-Methoxynicotinaldehyde

相似化合物

66572-55-2 26218-80-4 58584-63-7

上下游产品

2-methoxy-5-bromopyridine N,N-dimethyl-formamide 6-methoxynicotinonitrile (6-methoxypyridin-3-yl)methanol 6-oxo-1,6-dihydropyridine-3-carbaldehyde 6-methoxy-4-methylnicotinaldehyde 6-methoxy-5-methylnicotinaldehyde 2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxy-phenyl)-vinyl]-pyridine

2-甲氧基吡啶置于正丁基锂,溴,Sodium Acetate体系中,用 四氢呋喃,正己烷,二氯甲烷 作为反应溶剂,化学反应 17.5H,反应生成 6-甲氧基-3-吡啶甲醛
参考文献:金属螯合氨基酸可逆折叠β-发夹肽
标题:金属螯合氨基酸可逆折叠β-发夹肽
摘要:5-(1-羟基-吡啶-2-2 (1 H)-基)-1-丙氨酸(hop)是具有n-羟基-1,2-吡啶酮官能化的α-氨基酸,具有所需的dopa金属螯合性能(3,4-二羟基苯丙氨酸),但没有不需要的氧化还原活性.该fmoc-保护的氨基酸的fmoc-升-Hop(吨丁基)-Oh(11)从甘氨酸膦酸盐,随后的甲酯得到的合的酶水解来合成升在96%异构体ee值.氨基酸11在自动化肽合成用于14Merβ发夹肽的装配与序列[dsb 1,14 1 H-Ch Xetgkhghklvc‐oh(x = W,L‐ Hop).而10π电子含有的吲哚侧链升-Trp在肽14只完成一个疏水簇的形成,并且在90%的折叠的结果,折叠部分被显著降低为6的π电子大约30%升-Hop侧链在肽16中.由于ga(16)3三聚体的形成,Ga 3+的金属螯合将16的折叠重构到60%以上.16的螯合过程通过NMR光谱监测,随后ga 3+的释放 竞
DOI:10.1002/chem.201700698

专利信息

专利号:US-2024309003-A1
优先权日:2021-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN; PANDYA BHAUMIK; KAPLAN ALAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:CN-113321668-A
优先权日:2021-06-21
标题:Synthesis of Serpatinib

专利号:US-9938258-B2
优先权日:2012-11-29
标 题:Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
发明人：BALOGLU ERKAN; SHECHTER SHARON; SHACHAM SHARON; MCCAULEY DILARA; SENAPEDIS WILLIAM; GOLAN GALI; KALID ORI
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula I: n nor a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

专利号:US-8138188-B2
优先权日:2006-02-23
标题 :Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
发明人：ANDREWS MARK DAVID; BROWN ALAN DANIEL; LANSDELL MARK IAN; SUMMERHILL NICHOLAS WILLIAM
权利人:ANDREWS MARK DAVID; BROWN ALAN DANIEL; LANSDELL MARK IAN; SUMMERHILL NICHOLAS WILLIAM; PFIZER
摘要:The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) n nwherein the variables and substituents are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.

专利号:US-6413955-B1
优先权日:1999-10-04
标 题:Integrin receptor antagonists
发明人：ASKEW BEN C; SMITH GARRY R
权利人:MERCK & CO INC
摘要:The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

专利号:CN-110878043-A
优先权日:2019-11-18
标题 :A simple synthesis process of 6-methoxypyridine-3-carbaldehyde